Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cells added to fingolimod for relapsing-remitting multiple sclerosis
IRCT20191004044975N1Phase 3Completed
- Sponsor
- Vice-presidency for science and technology
- Start
- Feb 2020
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, single-blind trial of autologous bone marrow derived mesenchymal stromal cells and fingolimod in multiple sclerosis (MS) (2 arms), sponsored by Vice-presidency for science and technology. Primary endpoints: Safety and Clinical relapse rate. Started Feb 2020; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cellsfingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20191004044975N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191004044975N1.